FDA Revises Trial Requirements for Drug and Medical Product Approval

episode

Neurology® Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Planning Commission Meeting - Sep 17, 2026 1h 11m · 17 Sep 2026 · Leesburg Planning Commission

Heritage Commission - Sep 14, 2026 1h 57m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Historic District Review Committee - Sep 14, 2026 1h 36m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded31 Mar 2026

Publisherneurology.libsyn.com ↗

Handlerec:17517350

Show notes

Dr. Justin Abbatemarco talks with Lizzy Lawrence about the FDA's shift toward single-trial drug approvals and its implications for neurology, rare diseases, and broader effects on drug approval standards and healthcare access. Read the related article on STAT News. Disclosures can be found at Neurology.org.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in